Volume 12, Number 10—October 2006
Dispatch
Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa
Zhiquan Xiang*, Yan Li*, Ann Cun*, Wei Yang†, Susan Ellenberg†, William M. Switzer‡, Marcia L. Kalish‡, and Hildegund C.J. Ertl*
Table 2
Mean adenovirus neutralizing antibody titers for positive samples
| Origin | Mean VNA* titer ± standard deviation† |
|||
|---|---|---|---|---|
| AdHu5 | AdC68 | AdC6 | AdC1 | |
| Humans, United States | 116 ± 111 | 40 ± 0 | 20 ± 0 | 20 ± 0 |
| Humans, Thailand | 303 ± 353‡ | 20 ± 0 | 80 ± 44 | 33 ± 25 |
| Humans, Cameroon | 125 ± 114 | 109 ± 145 | 82 ± 52‡ | 58 ± 41 |
| Humans, Côte d'Ivoire | 162 ± 212 | 60 ± 51‡ | 37 ± 34‡ | 148 ± 275 |
| Humans, Nigeria | 165 ± 206 | 29 ± 20 | 80 ± 115‡ | 42 ± 23 |
| Chimpanzees, United States | 164 ± 233 | 201 ± 204 | 137 ± 160 | 64 ± 72 |
*VNA , virus neutralizing antibody.
†p values were determined by a Student t test to assess differences between titers in experimental samples and control samples. Human sera from the United States were used as a reference for antibodies to AdHu5, and chimpanzee sera were used as a reference for titers to AdC68, AdC6, and AdC1. Experimental samples in which >10 samples were positive for the given adenovirus are shown in boldface.
‡Samples that showed a statistically significant difference (p<0.05).
Page created: November 10, 2011
Page updated: November 10, 2011
Page reviewed: November 10, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.